[{"id":"73ab6272-0713-461d-b8bc-b9befd936cad","acronym":"MADILYM","url":"https://clinicaltrials.gov/study/NCT02617485","created_at":"2021-01-18T12:43:06.028Z","updated_at":"2024-07-02T16:35:31.754Z","phase":"Phase 3","brief_title":"MabionCD20 Compared to MabThera in Lymphoma Patients","source_id_and_acronym":"NCT02617485 - MADILYM","lead_sponsor":"Mabion SA","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • MabionCD20 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2023-10-25"}]